Перевести на Переведено сервисом «Яндекс.Перевод»

Analyst recommendations

The biotechnology sector has been incredibly successful in 2014 year. Its growth outperformed the growth of S&P 500  stunning 36%. Analysts at JP Morgan believe that a huge priority sector dynamics can decrease in 2015 year, but may remain the same level. The main drivers the success of biotech in 2014 were a high demand for the main products of the sector, the positive results of many clinical studies phase a wave of successful initial public offerings.
Date Company Who recommends Recommendation Target price
Waters Corporation BofA/Merrill Buy 140
Vertex Pharmaceuticals Incorporated Argus Buy 155
Universal Health Services Inc. Barclays Buy 150
UnitedHealth Group Incorporated Morgan Stanley Buy 140
Thermo Fisher Scientific, Inc. Argus Buy 145
Stryker Corporation Argus Buy 120
St. Jude Medical Inc. Deutsche Bank Buy 77
Regeneron Pharmaceuticals, Inc. Barclays Buy 593
Pfizer Inc. Morgan Stanley Buy 43
PerkinElmer Inc. UBS Buy 60
Mylan N.V. Barclays Buy 57
Merck & Co. Inc. UBS Buy 68
Mallinckrodt Public Limited Company Barclays Buy 80
Johnson & Johnson Deutsche Bank Buy 105
Intuitive Surgical, Inc. Barclays Buy 625
Humana Inc. Barclays Buy 223
HCA Holdings, Inc. UBS Buy 90
Gilead Sciences Inc. Deutsche Bank Buy 124
Express Scripts Holding Company RBC Capital Mkts Buy 95
Endo International plc Deutsche Bank Buy 88
1 2